[
  {
    "ts": "2026-01-13T08:02:39+00:00",
    "headline": "Biogen CEO Says New Drugs Offset MS Decline, Eyes 2026 “Transformational Era” at JPMorgan Conference",
    "summary": "Biogen (NASDAQ:BIIB) CEO Chris Viehbacher told investors the company has worked to stabilize its business as its multiple sclerosis (MS) portfolio continues to decline, while building new growth drivers and reshaping its cost structure. Speaking in a JPMorgan session moderated by analyst Chris Schot",
    "url": "https://www.marketbeat.com/instant-alerts/biogen-ceo-says-new-drugs-offset-ms-decline-eyes-2026-transformational-era-at-jpmorgan-conference-2026-01-13/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "c530faa1-d9f1-320b-9981-0332b8a8c9ab",
      "content": {
        "id": "c530faa1-d9f1-320b-9981-0332b8a8c9ab",
        "contentType": "STORY",
        "title": "Biogen CEO Says New Drugs Offset MS Decline, Eyes 2026 “Transformational Era” at JPMorgan Conference",
        "description": "",
        "summary": "Biogen (NASDAQ:BIIB) CEO Chris Viehbacher told investors the company has worked to stabilize its business as its multiple sclerosis (MS) portfolio continues to decline, while building new growth drivers and reshaping its cost structure. Speaking in a JPMorgan session moderated by analyst Chris Schot",
        "pubDate": "2026-01-13T08:02:39Z",
        "displayTime": "2026-01-13T08:02:39Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/f6cb92b1ab1bc201dca4d0e2002bf5de",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Biogen logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_.adyKbwRRIZ45mLKmAUSg--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/f6cb92b1ab1bc201dca4d0e2002bf5de.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6T8EpjLAYHJzuBQ89qxUSg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/f6cb92b1ab1bc201dca4d0e2002bf5de.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/biogen-ceo-says-new-drugs-offset-ms-decline-eyes-2026-transformational-era-at-jpmorgan-conference-2026-01-13/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-ceo-says-drugs-offset-080239656.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-13T18:00:00+00:00",
    "headline": "Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight",
    "summary": "The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & Johnson), Litifilimab (Biogen and Royalty Pharma), Ianalumab (Novartis), Cenerimod (Idorsia and Viatris), Rapcabtagene autoleucel (YTB323) (Novartis), KK-4277 (Kyowa Kirin), and others, and better diagnostic tools, which might improve the prognosis of the disease.New York, USA, Jan. 13, 2026 (GLOBE NEW",
    "url": "https://finance.yahoo.com/news/systemic-lupus-erythematosus-market-exhibit-180000729.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "30e61756-b6e9-3a33-b334-be2cf2ac213d",
      "content": {
        "id": "30e61756-b6e9-3a33-b334-be2cf2ac213d",
        "contentType": "STORY",
        "title": "Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight",
        "description": "",
        "summary": "The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & Johnson), Litifilimab (Biogen and Royalty Pharma), Ianalumab (Novartis), Cenerimod (Idorsia and Viatris), Rapcabtagene autoleucel (YTB323) (Novartis), KK-4277 (Kyowa Kirin), and others, and better diagnostic tools, which might improve the prognosis of the disease.New York, USA, Jan. 13, 2026 (GLOBE NEW",
        "pubDate": "2026-01-13T18:00:00Z",
        "displayTime": "2026-01-13T18:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/77011be1a12431fff8ed0ec458d52eca",
          "originalWidth": 7024,
          "originalHeight": 1774,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8_Pel.4JrEZSti8jSw_yLA--~B/aD0xNzc0O3c9NzAyNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/77011be1a12431fff8ed0ec458d52eca.cf.webp",
              "width": 7024,
              "height": 1774,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/khWS6pAsOLHy.c8Lh585qw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/77011be1a12431fff8ed0ec458d52eca.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/systemic-lupus-erythematosus-market-exhibit-180000729.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/systemic-lupus-erythematosus-market-exhibit-180000729.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVS"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "RPRX"
            },
            {
              "symbol": "IDRSF"
            },
            {
              "symbol": "KYKOF"
            }
          ],
          "premiumFinance": null
        },
        "storyline": null
      }
    }
  }
]